You are here:

Withdrawal of Zinbryta following reports of serious side effects

Published on

The manufacturers of Zinbryta (daclizumab) announce worldwide withdrawal of Zinbryta following new reports of serious side effects.

The European Medicines Agency (EMA) is currently reviewing a number of cases of serious brain inflammation (encephalitis and meningoencephalitis) in people taking Zinbryta.

Biogen and AbbVie, the companies which developed and market the drug, have announced that they are withdrawing Zinbryta worldwide.

The EMA advises that:

  • anyone currently taking Zinbryta should not stop without first talking to their neurologist or MS nurse
  • doctors should review anyone currently taking Zinbryta and discuss switching to an alternative treatment as soon as possible
  • no one should begin taking Zinbryta
  • anyone who has questions should talk to their neurologist or MS nurse

The company has also informed the EMA that it will stop ongoing clinical studies with Zinbryta in the EU. People in clinical studies who have any question should contact the doctor treating them in their study.

Zinbryta was approved in 2017 for NHS use as a disease modifying drug (DMD) for people with relapsing remitting MS who continued to have relapses despite taking at least two other DMDs.

Print this page